Figure 1: Limitations of conventional treatments for PD

One result from a recent meta-analysis caught my attention: people with Parkinson’s disease who received transcutaneous auricular vagus nerve stimulation, or taVNS, took longer strides on average, but they did not clearly walk faster.

That distinction is interesting because “walking better” is not one single outcome. Step length, speed, balance, freezing, posture, and confidence can all change differently.

Figure 2: PRISMA flow diagram of study identification, screening, and inclusion

------------------------------------------------------------------------------------------------------
👂 What did the researchers study?

The 2026 meta-analysis combined seven randomized controlled trials involving 183 people with Parkinson’s disease.

taVNS is a non-invasive approach that applies mild electrical stimulation to selected areas of the outer ear, where sensory fibers associated with the auricular branch of the vagus nerve can be accessed.

Compared with sham stimulation or other control conditions, the pooled results showed:

• Motor examination scores improved by an average of 2.64 points
• Stride length increased by approximately 13 cm
• Gait speed increased by 0.16 m/s, but this result was not statistically significant

The authors described the overall benefit as modest, and the certainty of evidence was rated as moderate because the total number of participants was still relatively small.

Figure 3: Forest plot showing the overall effect of taVNS on motor function in patients with PD

------------------------------------------------------------------------------------------------------

🧠 Why might stimulation at the ear influence movement?

Signals entering through auricular vagal pathways reach the brainstem and may interact with wider networks involved in autonomic regulation, attention, arousal, and motor control.

Researchers have also proposed possible effects on neurotransmitter systems, motor-network connectivity, inflammatory signaling, and abnormal brain rhythms associated with Parkinson’s disease.

However, those are still proposed mechanisms. This meta-analysis measured motor and gait outcomes; it did not directly prove that taVNS increased dopamine, reduced neuroinflammation, or slowed the progression of Parkinson’s disease.

------------------------------------------------------------------------------------------------------

🚶 Longer strides do not tell us everything

An increase in stride length may be encouraging, particularly because Parkinson’s disease is often associated with shorter, shuffling steps.

But it does not automatically mean that people experienced fewer falls, less freezing, better balance, or greater independence in daily life. Those outcomes need to be assessed separately and over longer periods.

------------------------------------------------------------------------------------------------------

🌱 The takeaway

This study does not establish taVNS as a replacement for medication, physical therapy, deep brain stimulation, or other established care.

What it does provide is an early signal that ear-based vagus nerve stimulation may be worth studying as an additional rehabilitation approach, particularly for selected aspects of movement and gait.

Larger trials with longer follow-up and more consistent stimulation protocols will be needed before we know who is most likely to benefit.

Has anyone here seen taVNS used alongside physical therapy or gait training for Parkinson’s disease? Which change would matter most to you: stride length, freezing, balance, walking speed, or non-motor symptoms?

Some people talk about “the vagus nerve” as if it is a single pathway that controls one specific function. But the reality is much more fascinating.

The vagus nerve is actually a complex network of nerve fibers that connects the brain with multiple organs, including the heart, lungs, and digestive system.

--------------------------------------------------------------------------------------------------------

🧠 It carries different types of information

The vagus nerve is not simply a signal from the brain telling the body what to do.

A large amount of communication travels from the body back to the brain, providing information about internal states, such as digestion, heart activity, and changes happening inside the body.

This constant exchange helps the brain understand what is happening throughout the body.

--------------------------------------------------------------------------------------------------------

🌱 Why does this matter?

It may help explain why our physical sensations and emotions can feel so connected.

For example:

• stress can be felt as stomach discomfort
• excitement can change your heart rate
• poor sleep can influence how your body feels the next day

The brain and body are constantly sharing information.

--------------------------------------------------------------------------------------------------------

🔬 Scientists are still learning more

Recent research is giving us a more detailed view of the vagus nerve, showing that it contains many different fibers with different roles rather than one simple “on/off” pathway.

The more we learn, the clearer it becomes that the nervous system is not just about sending commands, it is about communication.

--------------------------------------------------------------------------------------------------------

I’m curious: Have you ever experienced a moment when your body seemed to “know” something before your mind did?

For example, a gut feeling, physical reaction to stress, or changes in your body before you understood the reason?

Our brain and gut are connected through a complex communication pathway, the vagus nerve. In the previous post, we explored how scientists are creating detailed maps of the human vagus nerve to better understand its structure and connections.

But this raises another important question: Can we actively influence this pathway?

Researchers are now exploring different ways to modulate the vagus nerve and understand whether this could help regulate communication between the brain and the digestive system.

----------------------------------------------------------------------

🔌 Different Ways to Reach the Vagus Nerve

The vagus nerve can be studied and stimulated through several approaches.

1️⃣ Implantable Vagus Nerve Stimulation (iVNS)

This approach uses a surgically implanted electrode placed around the vagus nerve, usually in the neck.

✅ Potential advantages:

Direct access to the nerve

Established clinical applications in certain neurological conditions

⚠️ Limitations:

Requires surgery

Involves implantation risks and long-term device management

----------------------------------------------------------------------

2️⃣ Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS)

Instead of implantation, stimulation is delivered through the skin of the neck.

This approach is less invasive, but the neck contains complex anatomy, and achieving precise targeting remains an area of ongoing research.

----------------------------------------------------------------------

3️⃣ Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

This is the approach that has gained increasing research interest in recent years. taVNS applies mild electrical stimulation to specific areas of the outer ear without surgery.

Potential advantages include:

✅ Non-invasive

✅ Easier to administer

✅ Suitable for repeated stimulation studies

However, it is important to understand: The ear is not the only route to influence the vagus nerve. It is one of several approaches being explored because of its accessibility and safety profile.

----------------------------------------------------------------------

👂 Why Are Researchers Studying the Ear?

Certain regions of the outer ear contain sensory branches associated with the vagus nerve. Researchers are investigating whether stimulating these areas can influence networks involved in autonomic regulation and gastrointestinal function.

The proposed pathway is: 'Ear → Vagus nerve → Brainstem → Autonomic networks → Gut'. Through this pathway, researchers are studying possible effects on:

• gastrointestinal movement
• visceral sensations
• stress regulation
• inflammation-related pathways

This leads to a fascinating question: Can stimulation of the ear influence the way our gut functions?

----------------------------------------------------------------------

🔬 What Does Current Research Show?

Current studies suggest that taVNS may have potential benefits in some gastrointestinal conditions, although the evidence is still developing.

----------------------------------------------------------------------

🍽 Functional Dyspepsia (FD)

Functional dyspepsia is one of the areas with relatively stronger evidence. A multi-center randomized controlled trial involving 300 adults found that taVNS produced higher symptom improvement rates compared with sham stimulation, with some benefits continuing during follow-up.

----------------------------------------------------------------------

🚽 Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Some studies have reported improvements in:

• abdominal pain
• constipation-related symptoms
• autonomic nervous system indicators

These findings suggest that taVNS may influence brain-gut regulation in certain patient groups.

----------------------------------------------------------------------

⚠️ Chronic Constipation

The results are not always consistent. One randomized controlled trial in adults with chronic constipation did not find a clear benefit compared with sham stimulation.

This highlights an important point: The same stimulation approach may not work equally for every condition or every individual.

----------------------------------------------------------------------

🧠 The Gut-Brain Connection Is Complex

Why do different people respond differently? Because digestive health is influenced by multiple interacting systems:

• nervous system regulation
• stress responses
• sleep patterns
• immune activity
• individual differences

Researchers are still investigating:

❓ Who is most likely to benefit?

❓ Which stimulation location works best?

❓ What frequency and intensity are optimal?

❓ How long do the effects last?

Different studies use different stimulation protocols, making direct comparisons challenging.

----------------------------------------------------------------------

🌱 From Mapping the Nerve to Modulating the Nerve

From detailed anatomical mapping of the vagus nerve to non-invasive stimulation technologies, scientists are gradually learning how to better understand and interact with this communication system.

The goal is not simply to “stimulate a nerve.” The future of brain-gut medicine is moving toward:

🎯 more precise

🛡️ safer

🧩 more personalized

ways of regulating communication between the brain and the body.

I recently learned more about the vagus nerve and found the gut–brain connection surprisingly interesting. Many people know the vagus nerve as the “relaxation nerve”, but its role is much broader. It works like a communication pathway between the brain and the body, especially the digestive system.

A few interesting things:

🧠 The vagus nerve is a two-way communication system. It is not simply the brain sending commands to the body.

A large amount of vagus nerve signaling actually travels from the body back to the brain, carrying information about digestion, internal sensations, inflammation, and the state of the body. This is one reason why our emotions and physical sensations can feel so connected.

------------------------------------------------------

😰 Why does stress affect digestion so quickly?

Have you ever noticed:

• needing the bathroom before an important event
• losing your appetite when anxious
• feeling bloated during stressful periods

This happens because stress changes the balance of the autonomic nervous system. When the body enters a “high alert” state, digestion is no longer the priority. Over time, constant stress may influence gut movement, sensitivity, and digestive comfort.

------------------------------------------------------

😴 Sleep also plays a role

The gut has its own daily rhythm. Irregular sleep schedules can affect:

• digestion timing
• appetite signals
• gut sensitivity

The relationship goes both ways, poor sleep can affect the gut, and discomfort from the gut can make sleep harder.

------------------------------------------------------

🌱 The interesting takeaway:

Supporting the vagus nerve is not only about one technique or one device. Daily habits send signals to the nervous system:

• consistent sleep
• regular movement
• mindful breathing
• healthy eating patterns
• spending time outdoors

The body is a connected system, not separate parts working alone.

I’m curious, have you personally noticed a connection between stress and your gut? For example, does anxiety affect your digestion, appetite, or sleep?

Hong Kong Debut! Thank you to everyone who joined us at the 8.5 Press Conference! ❤️

We are bringing the science behind the Vagus Nerve to the Go Sleep Expo in Hong Kong.
Our compact wearable device is powered by neuromodulation technology, designed to help you relax, de-stress, and enjoy deep, natural sleep. 🌙

😊 Missed the press conference? No worries!
We'll be there every day during the official expo. Come say hi and experience it yourself!

📍 Booth: 3F-B24 (HKCEC, Hong Kong Convention and Exhibition Centre)
📅 Date: Aug 13 – 17, 2026

Come by for a 15-minute live demo and feel the calming power of neuro-tech.
We even have exclusive limited gifts waiting for you! 🎁

See you there! Make sure to follow us for the latest updates! 📍

https://reddit.com/link/1vgz87l/video/bfmr49qu2qhh1/player

Sleep doesn’t start when you close your eyes. It starts with how you transition from a busy day into a calmer state.

This August, our team will be at GO SLEEP 2026 in Hong Kong, sharing how ZenoWell combines ear-worn wellness technology, guided routines, and relaxation-focused experiences to help people build more mindful bedtime rituals.

At our booth, visitors can:

✨ Experience ZenoWell devices in a dedicated sleep environment 

✨ Explore how technology can become part of an evening wellness routine 

✨ Learn more about sleep, relaxation, and everyday recovery 

 

📍 Hong Kong Convention and Exhibition Center

📅 August 13–17, 2026

If you’re attending GO SLEEP 2026, we’d love to meet you.

When people explore vagus nerve stimulation (VNS), one common question comes up:

If different devices are all designed to stimulate the vagus nerve, why don't they all use the same settings?

Why does one device use a 10-minute session while another uses 20 or 30 minutes? Why do some devices have different modes? Why can two people have different experiences using the same device?

The answer is that VNS is not defined by a single setting. A stimulation experience depends on multiple factors, including stimulation location, electrode design, intensity, frequency, pulse width, session duration, and individual differences.

1. Why doesn't every VNS device use the same settings?

A stimulation protocol is a combination of many design choices. Researchers usually consider factors such as:

• where stimulation is applied;
• electrode design and contact quality;
• stimulation intensity;
• frequency and pulse width;
• session duration.

In research studies, these details are important because they allow scientists to compare different protocols and reproduce results. A consensus review on tVNS research recommended reporting factors such as electrode placement, intensity, frequency, pulse width, duty cycle, and session duration for this reason.

However, different devices may make different design choices because they may have different goals. A research protocol is usually designed to answer a specific scientific question, while a consumer device also needs to consider comfort, usability, and whether people can use it consistently in daily life.

Different settings do not automatically mean one device is better than another. They may simply reflect different design approaches.

2. Research-grade VNS vs Consumer VNS: What is the difference?

Research devices and consumer devices are built for different purposes.

A research device is designed around measurement and reproducibility. Researchers need to know exactly what stimulation protocol was used, including parameters, electrode placement, and session design.

A consumer device has another challenge: making the experience practical for everyday users. Comfort, ease of use, stable placement, and long-term usability all become important considerations.

This does not mean consumer devices should ignore scientific principles. It means the priorities can be different.

3. Why do different devices have different session duration?

Many people wonder: “Why does one device use 5 minutes, another use 20 minutes, and another use longer sessions?”

A longer session does not automatically mean stronger stimulation, and a shorter session does not automatically mean weaker stimulation.

Session duration is only one part of the overall protocol. It works together with factors such as stimulation intensity, location, electrode design, and stimulation pattern.

Research studies have used different session duration, and there is currently no single session length that is considered the universal best option for all non-invasive VNS applications.

For consumer devices, session duration also needs to consider real-world usage. A session that someone can comfortably include in their daily routine may be more practical than one that is difficult to maintain.

4. Why do different people feel different using the same device?

A common question is: “Why can one person feel stimulation at a low level while another person needs a higher setting?”

This is normal. Individual differences can affect the experience, including:

• ear anatomy;
• skin contact;
• electrode fit;
• sensitivity to stimulation.

Even with the same device, two people may have different sensations. A stronger sensation does not necessarily mean a better session. The goal is usually a comfortable and consistent experience.

A question for the community: When comparing VNS devices, what matters most to you?

• Stimulation parameters?
• Comfort and ease of use?
• Session length?
• Consistency of daily use?

Have you ever noticed that when you’re nervous, your stomach reacts before you even realize you’re stressed?

Maybe you suddenly lose your appetite, feel bloated, need to use the bathroom, or experience digestive discomfort during stressful moments.

This isn’t just “in your head.”

The gut and brain are connected through a complex communication network often called the gut-brain axis. Signals travel between the digestive system and the brain through multiple pathways, including the vagus nerve, a major communication pathway between the two systems.

When stress becomes chronic, it may disrupt this balance. Stress responses can influence cortisol levels, immune signaling, gut microbiome balance, and intestinal function, creating a cycle where stress affects digestion and digestive problems can increase stress.

But gut health isn’t only about supplements or digestion.

Research and emerging studies suggest that everyday habits play a major role:

🥗 Food
What we eat influences our gut microbiome and the metabolites produced by our gut bacteria. Diet is one of the biggest factors we can actively change.

😴 Sleep
Poor sleep can affect the gut-brain connection and the body’s stress response.

🏃 Exercise
Muscle health and movement are also connected with gut function. Reduced mobility and muscle loss may influence digestive health.

☀️ Sunlight & social connection
Lifestyle factors like daylight exposure and maintaining meaningful connections may also support overall wellbeing.

One area of growing interest is vagus nerve stimulation, including non-invasive approaches that stimulate branches of the vagus nerve near the ear. Early research is exploring how this pathway may influence nervous system balance and digestive function.

At ZenoWell, we’re exploring how wearable technology can support daily wellness routines around relaxation, stress management, and mind-body balance.

Curious:

Have you noticed your stress affecting your digestion?

What’s the biggest trigger for you, work stress, lack of sleep, diet, or something else?

Join us today for our live discussion:

The Gut-Brain Circuit: How Auricular Vagus Nerve Stimulation Restores Gut Health

The connection between the gut and the brain is one of the most fascinating communication systems in the human body. Through the gut-brain axis, signals constantly travel between the digestive system and the nervous system, influencing how we respond to stress, relaxation, and everyday changes.

In this session, we’ll explore:

Part 1: How Does Your Gut Talk to Your Brain?

Part 2: Why Does the Gut-Brain Connection Sometimes Become Disrupted?

Part 3: How Auricular Vagus Nerve Stimulation Restores the Gut-Brain Connection

📅 Date: Saturday, July 25, 2026
⏰ Time: 9:00 AM ET / 15:00 CET / 21:00 CST

Whether you’re new to the gut-brain connection or have already explored vagus nerve wellness, we’d love to have you join the conversation.

Vagus nerve stimulation is receiving increasing attention for sleep, stress management, relaxation, and other areas of health.

But what exactly is being stimulated and do all stimulation locations work the same way?

Here is a simple overview.

--------------------------------------------------------------------------------------------------------------

What is the Vagus Nerve?

The Vagus nerve is one of the main communication pathways between the brain and internal organs.

It's involved in functions such as heart rate, breathing, digestion, and the body's response to stress. It's also and important part of the parasympathetic nervous system, which helps the body shift away from a highly alert state and return toward rest and recovery.

However, the vagus nerve is not simply an “on/off relaxation switch.” It is a complex, two-way communication network.

--------------------------------------------------------------------------------------------------------------

What is vagus nerve stimulation?

Vagus nerve stimulation or VNS, uses controlled stimulation to influence signals traveling through vagal pathways.

There are several different approaches:

• Implanted VNS: A medical device is surgically connected t the vagus nerve in the neck.
• Transcutaneous cervical VNS: Stimulation is applied through the skin on the side of the neck.
• Transcutaneous auricular VNS or taVNS: Stimulation is applied to specific areas of the external ear.

These approaches are not interchangeable. They differ in location, electrode design, stimulation settings, evidence and intended use.

--------------------------------------------------------------------------------------------------------------

What may vagus nerve stimulation help with?

Researchers are studying VNS and taVNS in areas including:

• Sleep quality
• Stress regulation and relaxation
• Mood and emotional regulation
• Digestion
• Pain processing
• Attention and rehabilitation

Sleep is one of the more actively studied areas. A randomized sham-controlled trial found that a specific taVNS program reduced insomnia severity and improved sleep quality in people with chronic insomnia.

Small studies have also explored how taVNS may influence the body’s response to stress. For example, one study found a smaller initial heart-rate increase during a laboratory stress test, although participants did not report a significant difference in their subjective stress levels.

These results are promising, but they do not prove that every vagus nerve device improves sleep or relieves stress.

The outcome may depend on the exact device, stimulation location, settings, session length, and the person using it.

A more accurate statement is: Certain taVNS protocols may support sleep, relaxation, and stress regulation, but the evidence is still developing.

--------------------------------------------------------------------------------------------------------------

Which parts of the ear are used?

The external ear contains branches from several different nerves. This means that feeling a tingling sensation in the ear does not automatically prove that only the vagus nerve is being stimulated.

The most commonly discussed taVNS locations are:

Cymba conchae

The cymba conchae is the upper recessed area of the ear’s concha.

A frequently cited anatomical study found some vagus nerve supply in the cymba conchae in all 14 ears examined. Brain-imaging research has also found strong activation of vagal-related pathways when this area was stimulated.

Advantages:

• Strong anatomical rationale
• One of the most studied taVNS targets
• Strong brain-imaging support

Limitations:

• Small and recessed
• Electrode placement can be difficult
• Ear shape may affect contact and comfort

The cymba conchae is therefore considered one of the strongest candidate locations, but it should not be described as guaranteed to work best for everyone.

Cavum conchae

The cavum conchae is the lower part of the bowl-shaped area near the ear canal.

The same anatomical study found some vagus nerve supply in approximately 45% of the ears examined.

Advantages:

• Larger contact area
• Used in several taVNS studies
• Can be easier to reach with some electrode designs

Limitations:

• Mixed nerve supply
• Sensation may not come only from the vagus nerve

Tragus

The tragus is the small cartilage flap in front of the ear canal.

The classic anatomical study also identified some vagus nerve supply in approximately 45% of the examined ears.

Advantages:

• Easy to identify
• Convenient for clip-style electrodes
• Used in several research studies

Limitations:

• Nerve supply appears mixed and variable
• May also stimulate non-vagal sensory nerves
• Easy placement does not necessarily mean more selective stimulation

Earlobe

The earlobe is generally not considered a primary vagus nerve target. It is often used as a control or sham location in research because it is mainly supplied by other nerves.

--------------------------------------------------------------------------------------------------------------

What do the percentages actually mean?

The commonly quoted numbers, such as 100% for the cymba conchae and 45% for the tragus or cavum conchae, come from a small study of 14 ears from seven cadavers.

They do not mean:

• 100% of the nerves in the cymba conchae are vagal
• The cymba conchae provides 100% stimulation effectiveness
• A tragus device stimulates exactly 45% of the vagus nerve

They only describe how often researchers identified some vagus nerve supply in each area within that small sample. Individual anatomy can vary.

--------------------------------------------------------------------------------------------------------------

Is the stimulation location the only thing that matters?

No. Results may also be affected by:

• Electrode shape and size
• Contact quality
• Frequency and pulse width
• Intensity
• Session duration
• Individual anatomy
• The specific device and protocol

A poorly fitting electrode at a theoretically ideal location may be less consistent than a well-designed electrode that maintains stable contact at another studied location.

Stronger stimulation is also not automatically better. Stimulation should remain comfortable and follow the instructions for the specific device.

--------------------------------------------------------------------------------------------------------------

The main takeaway

Vagus nerve stimulation is not one uniform technology.

Research suggests that certain taVNS protocols may support sleep quality, relaxation, and stress regulation. However, the evidence varies depending on the device, stimulation location, settings, and intended use.

Among ear-based targets, the cymba conchae currently has one of the strongest anatomical and brain-imaging rationales. The tragus and cavum conchae are also commonly studied, but their nerve supply appears more mixed and variable.

Introduction A New Approach to Heart Failure

Shortness of breath after climbing a single flight of stairs, waking at night unable to breathe while lying flat, and recurrent swelling of both legs - for people with heart failure with reduced ejection fraction (HFrEF), these symptoms may signal a continuing decline in the heart's pumping capacity. Even with multiple standard medications and device-based therapies, some patients are repeatedly hospitalized and struggle to regain their quality of life.

In recent years, researchers have turned their attention to the vagus nerve, which links the brain and the heart. Conventional invasive vagus nerve stimulation (iVNS) requires a pulse generator to be implanted in the chest and an electrode to be wrapped around the cervical vagus nerve, creating practical barriers related to surgery, cost, and device management. Unlike transcutaneous auricular vagus nerve stimulation (taVNS), the treatment examined here uses implanted right cervical vagus nerve stimulation (VNS). It is not intended to replace foundational therapies such as diuretics or renin-angiotensin system inhibitors; rather, it aims to correct persistent neural dysregulation alongside medical treatment. The ANTHEM-HFrEF trial therefore asked a pivotal question: can long-term VNS reduce cardiovascular death and heart failure hospitalization when added to guideline-based care?

Research Background A Two-Way Brain-Heart Dialogue

Heart failure is more than a weak heart muscle. It is also accompanied by an imbalance in the autonomic nervous system (ANS): sympathetic activity remains chronically elevated, while parasympathetic influence is relatively diminished. The former acts like a continuously depressed accelerator, increasing heart rate, constricting blood vessels, and raising myocardial oxygen demand. The vagus nerve functions more like a brake and a homeostatic regulator, helping govern heart rate, inflammation, and cardiac electrical activity.

The vagus nerve contains numerous afferent fibers that relay information from the internal organs to the brain, as well as efferent pathways that regulate the heart. Signals generated by VNS can enter autonomic networks in the brainstem and alter sympathetic and parasympathetic tone through central-peripheral circuits. Earlier small studies suggested that VNS might improve heart rate variability (HRV), exercise capacity, and quality of life. However, stimulation side, intensity, and dose-titration strategies differed across trials, and clinical outcomes remained inconclusive. Importantly, an improvement in a questionnaire score is not equivalent to a reduction in death or hospitalization: the former reflects how patients feel, whereas the latter directly measures disease burden.

ANTHEM-HFrEF was therefore designed as a pivotal trial. Rather than focusing only on whether echocardiographic measures improved, it placed hard outcomes such as cardiovascular death and heart failure hospitalization at the center of the evaluation and examined whether stimulation could sustain autonomic engagement over time.

Figure 1. Autonomic imbalance in heart failure and the therapeutic rationale for VNS. The central illustration shows sympathetic overactivity and inadequate parasympathetic regulation in HFrEF, together with the proposed pathway through which VNS may influence cardiac function via central autonomic networks. It also summarizes trial enrollment, treatment allocation, and the main study endpoints.

Methods How the Treatment Was Tested

This open-label, randomized, controlled, multicenter pivotal trial enrolled 532 patients with HFrEF. Eligible participants had a left ventricular ejection fraction (LVEF) of 35% or lower, New York Heart Association (NYHA) functional class II or III symptoms, and an N-terminal pro-B-type natriuretic peptide (NT-proBNP) level of at least 800 pg/mL. All participants were receiving stable guideline-directed medical therapy (GDMT).

Participants were randomized in a 2:1 ratio: 358 received right cervical VNS plus GDMT, and 174 received GDMT alone. The implanted system consisted of a subcutaneous pulse generator in the chest connected to an electrode on the right cervical vagus nerve. After implantation, stimulation was gradually titrated to 2.0-3.0 mA at 5-10 Hz, with a pulse width of 250 microseconds and a cycle of 18 seconds on and 66 seconds off. Changes in heart rate (HR) and HRV were used to confirm autonomic engagement. The choice of the right side was deliberate: the system sought to achieve stable autonomic engagement at a tolerable intensity while establishing an individualized dose through continued titration.

The primary efficacy endpoint was time to first cardiovascular death or heart failure hospitalization. The primary safety endpoint was freedom from serious implantation- or system-related adverse events within 90 days. Additional measures included 6-minute walk distance (6MWD), the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), NYHA class, and LVEF. Deaths and hospitalizations were adjudicated by an independent committee, while walking tests and NYHA class were assessed by blinded evaluators. The adaptive design originally allowed enrollment of up to 1,000 patients, but the sponsor stopped recruitment early for reasons unrelated to either efficacy or futility. As a result, the trial did not accumulate the planned amount of statistical information.

Results The Primary Answer Was Not Positive

In the intention-to-treat (ITT) population, the primary endpoint occurred in 34.6% of the VNS group and 40.2% of the control group. The hazard ratio was 0.84, with a 95% confidence interval (CI) of 0.62-1.12 and a 1-sided P value of 0.115, which did not meet the prespecified threshold for statistical significance. In other words, although the curves favored VNS, the true effect could still range from meaningful benefit to no benefit. The separation of the curves alone cannot establish treatment success, and a favorable trend should not be presented as proven efficacy. For first heart failure hospitalization, the hazard ratio was 0.80 (95% CI, 0.59-1.10; P=0.083). For cardiovascular death, it was 0.90 (95% CI, 0.58-1.42; P=0.332). Neither result was conclusive. Heart failure hospitalization rates per patient-year were 0.38 in the VNS group and 0.43 in the control group, again without definitive evidence of benefit. The between-group difference in LVEF change was -0.45 percentage points (P=0.765), indicating no confirmed improvement in cardiac pumping function.

Some outcomes nevertheless showed encouraging signals. At 9 months, KCCQ-OSS improved by 7.3 points more in the VNS group than in the control group (95% CI, 3.02-11.61; P<0.001), suggesting better patient-reported symptoms, physical limitations, and quality of life. Under one method of handling missing data, 6MWD improved by an additional 16.2 m, and NYHA class was also more likely to improve. An exploratory hierarchical win-ratio analysis incorporating death, heart failure hospitalization, and KCCQ-OSS yielded a value of 1.25 (95% CI, 1.00-1.55; P=0.023). However, quality of life contributed substantially to this composite result, and participants could not be fully blinded to whether a device had been implanted. The finding is therefore better viewed as a hypothesis for future trials than as a substitute for the neutral primary endpoint.

For safety, 96.7% of patients were free from serious implantation- or system-related adverse events within 90 days (95% CI, 94.1%-98.3%; P<0.001), meeting the prespecified target. During follow-up, serious adverse events occurred in 59.4% of the VNS group and 59.2% of the control group; mortality was 24.0% and 26.4%, respectively. Overall, these rates were similar between groups.

Figure 2. Kaplan-Meier curves. The upper panel shows freedom from the first occurrence of cardiovascular death or heart failure hospitalization; the lower panel shows freedom from first heart failure hospitalization. Green represents VNS plus GDMT, and blue represents GDMT alone. The vertical axis indicates the proportion of patients who remained free of the relevant event, and the horizontal axis shows follow-up time in weeks. Although both curves favored VNS, the hazard ratio for the primary composite endpoint was 0.84 (95&#37; CI, 0.62-1.12; P=0.115), which did not meet the prespecified significance threshold. Numbers beneath the graph indicate the patients remaining at risk at each time point.

Mechanistic Interpretation After the Neural Target Was Engaged

Although the primary clinical endpoint was neutral, 24-hour electrocardiographic recordings showed a sustained increase in the standard deviation of normal-to-normal intervals (SDNN) in the VNS group relative to baseline and the control group. This suggests that the device achieved durable autonomic modulation rather than producing only a short-lived response after implantation. HR did not decline consistently, indicating that VNS does not simply slow the heartbeat. Instead, it may alter the dynamic regulation of beat-to-beat intervals. The result also highlights an essential distinction: engaging a biological target is not the same as improving a disease outcome.

Physiologically, right cervical VNS may influence brainstem autonomic centers through afferent signaling, rebalance sympathetic and parasympathetic output, and potentially reduce an unfavorable inflammatory environment through neuroimmune pathways. The combination of improved HRV, better patient-reported outcomes, and unchanged LVEF suggests that any potential benefit may not arise from stronger contraction with each heartbeat. Instead, it could reflect a combination of altered symptom perception, circulatory regulation, and exercise tolerance.

Exploratory composite outcomes can be influenced by the open-label design, subjective questionnaires, and multiple comparisons. The most accurate interpretation is therefore not that VNS has already been shown to treat heart failure, but that the autonomic target was successfully engaged while the signal of clinical benefit still requires confirmation. This is also the study's most important scientific contribution.

Figure 3. Win-ratio outcome. This figure presents the prespecified exploratory hierarchical composite outcome, comparing patient pairs in sequence for cardiovascular death, heart failure hospitalization, and KCCQ-OSS. A green bar extending farther to the right favors VNS. The overall win ratio was 1.25 (95&#37; CI, 1.00-1.55; P=0.023). Because the quality-of-life component contributed substantially to the composite, this analysis is hypothesis-generating and cannot replace the neutral primary efficacy endpoint.

Future Directions From Biological Signal to Clinical Benefit

In the future, the significance of VNS may extend beyond heart failure treatment and help establish neurocardiology as a broader interdisciplinary field. By clarifying the two-way communication among the brain, autonomic nervous system, immune system, and cardiovascular system, researchers may build more complete models of heart failure regulation and explore the application of VNS in arrhythmias, hypertension, and other cardiovascular conditions.

Neuromodulation could also be integrated with wearable sensors, artificial intelligence, and remote-care platforms. Continuous monitoring of HR, HRV, exercise capacity, and symptoms may enable closed-loop systems that automatically adjust stimulation parameters in response to a patient's real-time physiological state.

In addition, implanted VNS and taVNS may form a tiered pathway spanning noninvasive screening, early intervention, and long-term precision treatment. Vagus nerve modulation could thereby evolve from a single medical device into an integrated health-management strategy encompassing prevention, treatment, and rehabilitation.

Reference

1. Konstam MA, Udelson JE, Mann DL, et al. Vagal nerve stimulation in patients with heart failure and reduced ejection fraction: The ANTHEM-HFrEF trial[J]. Journal of the American College of Cardiology, 2026, 87(25): 3490-3502. 10.1016/j.jacc.2026.03.040.

Introduction: The Hardest-to-See Side of Schizophrenia

When people think of schizophrenia, the first symptoms that often come to mind are the more “visible” ones, such as hallucinations, delusions, or feelings of being persecuted. But in clinical practice, there is another group of symptoms that is quieter and often more difficult to address: patients may become emotionally flat, less willing to speak, less motivated, socially withdrawn, and no longer interested in things that once brought them pleasure. These are known as negative symptoms.

Negative symptoms often attract less attention than positive symptoms, yet they can profoundly affect a patient’s quality of life, social functioning, and long-term prognosis. What makes them even more challenging is that in patients with treatment-resistant schizophrenia, or TRS, negative symptoms often persist and respond only modestly to conventional antipsychotic medications. As a result, researchers have begun looking for new approaches beyond medication: Could noninvasive neuromodulation help loosen the grip of these “silent symptoms”?

This study, published in Molecular Psychiatry, focuses on transcutaneous auricular vagus nerve stimulation, or taVNS. It aims to answer a very specific question: As an adjunctive treatment, can transauricular vagus nerve stimulation improve TRS characterized predominantly by negative symptoms?

Research Background: Why Stimulate the Ear?

taVNS has attracted attention because the vagus nerve is involved not only in the regulation of heart rate, gastrointestinal function, and inflammation, but also in connections with brain networks involving the brainstem, limbic system, and prefrontal cortex. Certain regions of the auricle contain the auricular branch of the vagus nerve, or ABVN. By applying electrical stimulation to the ear, researchers hope to influence VN-related pathways in a noninvasive way.

For the negative symptoms of schizophrenia, researchers are particularly interested in two possible mechanisms. The first is brain-network modulation. Previous studies suggest that negative symptoms may be associated with abnormal neural oscillations and reduced connectivity in regions such as the frontal and temporal lobes. The second is inflammation regulation. Patients with TRS may have a chronic inflammatory state, with elevated pro-inflammatory cytokines such as tumor necrosis factor-alpha, or TNF-alpha, and interleukin-6, or IL-6. These inflammatory signals may be related to negative symptoms, reduced motivation, and abnormal reward processing.

Figure 1: The taVNS electrodes are placed on the left cymba conchae and tragus. The right side shows a mechanistic illustration of changes in symptom scores, EEG coherence, and TNF-alpha.

VN stimulation is believed to potentially activate the cholinergic anti-inflammatory pathway and inhibit the release of pro-inflammatory factors. At the same time, taVNS may also modulate brain networks related to emotion, interoception, and cognitive control. Therefore, this study not only examined whether symptoms improved, but also explored whether TNF-alpha and EEG coherence could serve as biomarkers of treatment sensitivity.

Research Methods: 50 Patients, Active Stimulation Versus Sham Stimulation

This was a 4-week, double-blind, randomized, sham-controlled clinical trial conducted at Kunming Psychiatric Hospital in China. A total of 50 inpatients with TRS characterized predominantly by negative symptoms were enrolled and randomly assigned to either the active taVNS group or the sham stimulation group, with 25 patients in each group.

Patients were 18 to 65 years old, met diagnostic criteria for schizophrenia, and fulfilled the definition of TRS. Their antipsychotic medication dosage had been stable for at least 2 months before enrollment and remained stable during the study. The study specifically required that patients have predominantly negative symptoms. Their negative-symptom factor score on the Positive and Negative Syndrome Scale, or PANSS-FSNS, had to be 24 or higher, and they had to meet certain severity thresholds on items such as blunted affect, passive or apathetic social withdrawal, and lack of spontaneity and flow of conversation.

The intervention lasted 2 weeks, followed by a 2-week follow-up period. Both active taVNS and sham stimulation were administered twice daily, 5 days per week, for a total of 20 sessions. Electrodes were placed on the left cymba conchae and tragus. The active stimulation parameters were 25 Hz, a pulse width of 250 μs, a 30-second on/off cycle, and a current intensity adjusted within the range of 0.1 to 3 mA. The intensity was set at the midpoint between the sensory threshold and the pain threshold. In the sham group, the electrodes were placed at the same sites, but current was delivered only briefly at the beginning and end of the session to simulate the sensory experience as much as possible.

Figure 2: Patients were screened from hospitalized TRS patients, and a final total of 50 patients were randomly assigned to the active taVNS group or the sham stimulation group. Rating scales and biomarker assessments were conducted multiple times at baseline, during treatment, and during follow-up.

Research Results: Symptoms Began to Shift

The primary outcome was the change in PANSS-FSNS after 2 weeks of treatment. The intention-to-treat analysis showed that improvement in negative symptoms was greater in the active taVNS group than in the sham stimulation group. The mixed-effects model showed a significant time-by-group interaction for PANSS-FSNS, with F = 3.26 and p = 0.013. At the end of treatment, the difference in PANSS-FSNS change between the active taVNS group and the sham group was -1.36, with a 95% CI of -2.60 to -0.12, an effect size of -0.62, and p = 0.033.

More importantly, this improvement did not disappear immediately after treatment ended. At the first week of follow-up, the active taVNS group still performed better than the sham group, with a PANSS-FSNS change difference of -2.00 and p = 0.002. By the end of follow-up, the active taVNS group continued to maintain an advantage, with a difference of -1.32 and p = 0.038.

Similar findings were also observed on the PANSS negative-symptom subscale. At the end of treatment, improvement was more pronounced in the active taVNS group, with a between-group change difference of -1.28 and p = 0.020. The difference persisted during follow-up. In terms of safety, taVNS was generally well tolerated28 and p = 0.020. The difference persisted during follow-up. In terms of safety, taVNS was generally well tolerated, and no serious adverse events were reported during the study. One patient in the active taVNS group experienced brief nausea after 1 week of treatment. No medical intervention was needed, but the patient withdrew from the study due to personal concerns.

Figure 3: The trend in PANSS-FSNS changes over 4 weeks in the active taVNS group and sham stimulation group. The active taVNS group showed a more pronounced decrease in negative-symptom factor scores at the end of treatment and during follow-up, suggesting greater improvement in negative symptoms.

Mechanistic Exploration: Inflammatory Signals and Brain Networks Offer Clues

The most valuable aspect of this study is not only that “symptoms improved,” but also that it further explored who may be more sensitive to taVNS and which biological pathways may be involved in the improvement.

The researchers measured several inflammatory cytokines, including TNF-alpha, interleukin-1 beta, or IL-1β, interleukin-2, or IL-2, and IL-6. The results showed that these inflammatory factors decreased in both groups after treatment. However, in the active taVNS group, changes in TNF-alpha were significantly correlated with improvement in PANSS-FSNS, with r = 0.56 and an adjusted p = 0.017. This correlation was not observed in the sham stimulation group. This suggests that TNF-alpha may be a candidate marker of sensitivity to taVNS treatment.

The study also analyzed resting-state electroencephalography, or EEG, coherence. EEG coherence can be broadly understood as the degree of synchronization in electrical activity between different brain regions. In the active taVNS group, baseline beta-band coherence between the left frontal and left parietal regions, specifically F3-P3, was associated with improvement in negative symptoms after treatment, with r = 0.68 and an adjusted p = 0.017. At the same time, changes in F3-P3 beta-band coherence after treatment were also correlated with improvement in PANSS-FSNS, with r = -0.56 and p = 0.004. Similar relationships were not observed in the sham stimulation group.

Figure 4: In the active taVNS group, changes in TNF-alpha, baseline F3-P3 beta-band coherence, and post-treatment changes in F3-P3 beta-band coherence were all associated with improvement in PANSS-FSNS. No similar pattern was observed in the sham stimulation group.

This suggests that taVNS may not simply be “stimulating the ear.” Instead, it may simultaneously engage neuroimmune pathways and frontoparietal brain networks. For patients whose main symptoms include emotional blunting and lack of motivation, these network changes may become important clues for more precise identification of suitable patient groups in the future.

In the active taVNS group, changes in TNF-alpha, baseline F3-P3 beta-band coherence, and post-treatment changes in F3-P3 beta-band coherence were all associated with improvement in PANSS-FSNS. No similar pattern was observed in the sham stimulation group.

Future Outlook: From “Standardized Stimulation” to Precision Modulation

The value of taVNS in psychiatry may go beyond improving a single scale score. Its greatest potential lies in providing a low-burden, repeatable, and potentially long-term neuromodulation entry point, offering a new adjunctive intervention option for symptoms that respond poorly to medication. For clinical problems such as negative symptoms, which progress slowly, require long recovery cycles, and depend on ongoing rehabilitation support, taVNS may have the opportunity to work alongside medication, cognitive training, social-function rehabilitation, and digital follow-up to form a more complete long-term management pathway.

With advances in EEG, inflammatory biomarkers, heart rate variability, and wearable devices, taVNS may also move from “fixed-parameter stimulation” toward “individualized modulation.” Future studies may use patients’ brain-network status, inflammatory markers such as TNF-alpha, autonomic nervous system activity, and symptom fluctuations to identify those most likely to benefit. Stimulation parameters, treatment course, and intervention timing could then be dynamically adjusted, bringing treatment closer to precision medicine.

The clinical application of taVNS may eventually expand from negative symptoms of schizophrenia to brain-body regulation-related conditions such as depression, anxiety, cognitive decline, sleep disorders, and addiction. What makes it truly worth anticipating is its potential to develop “noninvasive ear stimulation” into a regulatory platform that connects brain networks, immune inflammation, and the autonomic nervous system, opening new possibilities for the long-term rehabilitation of psychiatric disorders.

Reference

Cui Y, Sun J, Zhang B, et al. Efficacy and safety of transcutaneous auricular vagus nerve stimulation for patients with treatment-resistant schizophrenia with predominantly negative symptoms: a randomized clinical trial and efficacy sensitivity biomarkers. Molecular Psychiatry 30 (2025): 5437–5447.
https://doi.org/10.1038/s41380-025-03132-8

Latest VNS Literature

1. Control of spatiotemporal activation of organ-specific fibers in the vagus nerve. https://www.nature.com/articles/s41467-025-59595-4
2. Application of kilohertz-frequency block to mitigate off-target motor effects of vagus nerve stimulation in swine. https://doi.org/10.1038/s41467-025-67823-0
3. Transcutaneous vagus nerve stimulation enhances episodic memory across valences and memory stages. https://doi.org/10.1016/j.brs.2026.103051
4. Non-invasive transcutaneous vagus nerve stimulation during memory retrieval enhances recollection of emotionally salient memories. https://www.nature.com/articles/s41598-026-53772-1
5. Transauricular Vagus Nerve Stimulation in Acute Ischaemic Stroke Requiring Mechanical Thrombectomy: Sham-Controlled, Randomised Device Trial. https://doi.org/10.1007/s12975-025-01404-7
6. Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial. https://doi.org/10.1007/s12975-025-01405-6
7. Pharmacological and transcutaneous auricular vagal targeting of endoplasmic reticulum stress in the trigeminal ganglion alleviates migraine-like behaviors. https://doi.org/10.1186/s10194-026-02400-4
8. Long-term vagus nerve stimulation synergized with rapamycin elicits neuroimmune modulation to prolong skin allograft survival. https://doi.org/10.1016/j.isci.2026.

The gut and brain are constantly communicating through multiple pathways, and the vagus nerve is one of the most interesting connections being studied in neuroscience.

Many people are familiar with the gut-brain axis, but there are still many open questions:

• How does the gut actually send signals to the brain?
• Why can this communication become disrupted under stress or inflammation?
• Can non-invasive approaches influence this connection?

These questions are also the focus of an upcoming neuroscience discussion we are hosting on July 25 with Dr. Jane, a neuroscience researcher at The Chinese University of Hong Kong and ZenoWell’s chief scientist.

The discussion: The Gut-Brain Circuit: How Auricular Vagus Nerve Stimulation May Influence Gut-Brain Communication

Topics include:

• How does your gut talk to your brain?
• Why does the gut-brain connection sometimes become disrupted?
• What role might auricular vagus nerve stimulation play?

Before the discussion, we’d love to hear from this community, What questions would you ask a neuroscience researcher about the gut-brain connection?

Hello everyone, we are the ZenoWell team.

Over the past few weeks, we have received a lot of genuine feedback from users about our current electrode earpiece. Some say the wearing experience is not ideal, others have reported unstable connections, and some feel that the electrode earpiece have become the weakest link in the entire device.

These comments are very valid, and we take them extremely seriously. To that end, we sincerely invite ZenoWell users to participate in the trial testing of our brand‑new pure silicone electrode earpiece.

Of course, we would like to make it clear that this is not a clinical trial, not a medical study, and does not constitute any therapeutic claims. We are not trying to verify the effectiveness of the electrodes in improving specific conditions; instead, we are focusing on the actual performance of the new design in the following areas:

• Fit
• Comfort
• Contact stability
• Ease of use in daily life
• Adaptability and friendliness to different ear shapes

If you already own our device and are interested in participating in the trial, please send us a direct message. We welcome any honest feedback, even if the new electrode earpiece still have shortcomings, please feel free to tell us exactly that. If you later choose to share your trial experience publicly, please note that you received the beta version of our electrodes.

Finally, thank you once again to all the users who have already provided feedback. It is precisely this kind of information from real‑world usage scenarios that helps us continuously refine the most important details of our product.

Some nights I fall asleep normally and sleep through most of the night.

But on other nights, I wake up in the middle of the night and stay awake for anywhere from 20 minutes to over an hour before eventually falling back asleep.

It feels quite random, and I haven’t been able to clearly link it to stress, diet, or anything obvious.

I’m curious if this is something other people experience as well, and how you usually think about it when it happens.

Hi All, I’ve been spending a lot of time recently reading and working around stress, sleep, and autonomic regulation, especially anything related to the vagus nerve.

One thing that keeps surprising me is how polarized people’s reactions are to this whole area.

Some people immediately connect with the idea that the vagus nerve plays a role in stress regulation, recovery, and sleep quality, and are open to exploring non-pharmaceutical approaches in that direction.

Others are very skeptical of anything that sounds like “nervous system stimulation” or wearable interventions, and prefer approaches like sleep hygiene, exercise, therapy, or medication, which is completely understandable.

What I’m still trying to understand is not the biology itself, but the trust boundary people have with this category.

At what point does something feel:

• Scientifically grounded vs speculative
• helpful vs over hyped
• "wellness tool" vs "marketing story"

I don’t think I have a clear answer yet.

So I’m genuinely curious from people here:

• What makes you personally trust (or distrust) this kind of approach?
• Is vagus nerve stimulation something that feels meaningful to you, or more like wellness trend language?
• Where do you personally draw the line with wearable health tech?

I’d really appreciate honest opinions, especially skeptical ones.

Hi all! Last week, Dr. Jane hosted a live talk around one simple question: What does great sleep mean to you?

Well, we did not want to turn it into a talk about “perfect sleep.” Most people are not sleeping just to get a high score on a wearable. They simply want to wake up feeling a little more restored, a little less tense, and a little more ready for the day.

1. Great sleep is not just about hours

Sometimes you sleep eight hours and still feel terrible. Sometimes six and a half hours feels surprisingly okay. A green score on a wearable can be helpful, but it does not always tell the full story.

Sleep quality also includes how long it takes to fall asleep, how often you wake up during the night, how much time you actually spend asleep, and how you feel the next morning. One point that stood out from the talk was that falling asleep extremely fast is not always a good sign. Sometimes it simply means your body is very tired and needs more recovery.

2. Wearable is helpful, but one night is not the whole story

Devices like WHOOP, Oura, Apple Watch, or Garmin can help people understand their sleep patterns. They can estimate sleep stages, recovery, HRV, and readiness, but they are not the same as a sleep lab.

The more useful part is the trend over time. One bad score does not mean something is wrong with you. It may be more helpful to ask what keeps showing up again and again. Was it late caffeine, a heavy dinner, a stressful week, too much light at night, or not enough morning sunlight?

3. Sleep affects more than sleep

Poor sleep can make the next day feel harder in ways that are easy to recognize. Stress can feel bigger, small things can become more irritating, recovery can feel slower, digestion can feel different, and even normal conversations can take more energy than usual.

Sleep is connected with stress, recovery, digestion, and the way we connect with ourselves and other people. Not in a dramatic way, but in the everyday way many of us have probably felt before.

4. Better sleep starts long before bedtime

A lot of people only think about sleep at night, but sleep is shaped by the whole day. Dr. Jane talked about small habits like getting morning sunlight before checking your phone, taking a short walk if possible, drinking water after waking, being careful with caffeine timing, keeping naps short, avoiding heavy meals and alcohol close to bed, using warm dim light in the evening, reading something boring instead of scrolling, and keeping the bed mainly for sleep.

None of these habits are very exciting. But that may be the point. Sleep is often built through small things repeated over time, not through one perfect nighttime trick.

5. A routine should make you less anxious, not more

Tracking can be useful, but if tracking makes you more stressed, something is off. The goal is not to chase a perfect score. The goal is to understand your own patterns a little better.

That also applies to vagus nerve routines and taVNS. We do not see it as a magic fix. For some people, it may become one part of a wind-down routine. For others, simple habits like light, timing, breathing, temperature, and screen boundaries may matter more. Real life is messy, people respond differently, and some changes may only show up after a week or two.

So we keep coming back to the same idea: watch the trend, pay attention to how you feel, and build routines you can actually repeat.

Hi all. We wanted to share a new blog written by Dr. Jane, ZenoWell’s co-founder and Chief Scientist, on vagus nerve stimulation, longevity, and what it means to “live more.”

A lot of longevity conversations focus on adding more years. But for many people, the more immediate question is simpler:

• Can I sleep better?
• Can I recover from stress more easily?
• Can my body feel less stuck in high-alert mode?
• Can I keep moving, connecting, and feeling present in daily life?

The article looks at the vagus nerve through five daily pillars:

• Sleep
• Stress resilience
• Movement and exercise recovery
• Nutrition, metabolism, and the gut-brain connection
• Connection with ourselves and others

One idea we really like is that longevity is not just about living longer. It is about protecting the quality of the years we already have.

The vagus nerve is part of many systems people talk about here all the time: sleep, stress, digestion, HRV, recovery, emotional regulation, and the body’s ability to shift between alertness and rest.

Of course, vagus nerve stimulation is not a magic fix, and real-world experiences can vary a lot. Some people notice changes in sleep first. Some track HRV but do not immediately “feel calm.” Some need slower routines, lower intensity, or more time to understand what actually works for their body.

That gap between research, biomarkers, and lived experience is one of the reasons we want to keep having conversations here.

We would also be curious to hear how people here think about longevity. Is it sleep? Energy? Less stress? Better recovery? Feeling more connected to your body?